皮肤肌炎的阿尼弗罗卢马布治疗:耐火患者的新见解
Linda Carli1, Lorenzo Cavagna2, Chiara Cardelli3
1L. Carli, PhD, Rheumatology Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; European Reference Network ReCONNET, EU.
The Journal of rheumatology
|November 1, 2025
概括
在耐火性皮肤肌肉炎 (DM) 患者中,阿尼弗洛卢马布显著改善了皮肤和肌肉症状. 这项研究强调了anifrolumab.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 皮肤性皮质肌肌炎 (DM) 带来了重大挑战,特别是在耐火病例中.
- 一种类型的干扰素途径与DM的病变发生有关.
- 对于患有严重皮肤DM且对标准治疗无反应的患者,治疗选择有限.
研究的目的:
- 评估阿尼弗罗卢马布在耐火性皮肤DM患者的疗效和安全性.
- 评估阿尼弗罗卢马布对皮肤活动,肌肉参与和生活质量的影响.
- 为了探索阿尼弗罗卢马布的潜在的葡萄糖皮质体节约作用.
主要方法:
- 对4名耐火性皮肤DM患者的回顾性分析,这些患者接受了anifrolumab治疗.
- 皮肤皮质肌肉炎疾病区域和严重性指数活动 (CDASI-A) 用于皮肤评估.
- 手动肌肉测试-8 (MMT-8),患者总体评估 (PtGA) 和每日葡萄糖皮质激素 (GC) 剂量进行了监测.
主要成果:
- 平均CDASI-A的显著降低,从27降至8.75.
- 平均MMT-8从67.5提高到71.3,平均PtGA从7.5提高到1.5.
- 平均每日GC剂量从10毫克降低到4毫克的普得尼松,表明GC节约效应.
结论:
- 阿尼弗罗卢马布在改善耐火性皮肤DM的皮肤和肌肉表现方面表现出显著的有效性.
- 阿尼弗罗卢马布治疗导致了患者报告结果的改善,并减少了葡萄糖皮质激素依赖.
- 阿尼弗罗卢马布为耐火性皮肤DM患者提供了一个有前途且安全的治疗选择.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
476
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
476
Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
423
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
423
Inflammatory Bowel Disease IV: Pharmacological Management
463
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
463
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K


